PFD6

PF3D7_0512000 (PfPFD6) is a subunit of the P. falciparum prefoldin co-chaperone system, participating in formation of the heterohexameric prefoldin complex together with the other five parasite prefoldin subunits (PFD1–5) (PMID:38925325). Consistent with a chaperone role, PfPFD6 physically engages client proteins including merozoite surface protein-1 (MSP-1) (PMID:33145997) and α-tubulin-I (PMID:38925325), interactions that are disrupted by the FDA-approved drug Biperiden, which blocks prefoldin complex assembly (PMID:38925325). PfPFD6 also interacts with Kelch13 in intraerythrocytic parasites, and heterologous expression of PfPFD6 in yeast PFD6 mutants confers an artemisinin-resistance phenotype, establishing a causative functional link between PfPFD6 and the artemisinin resistance mechanism (PMID:38925325). PfPFD6 is expressed predominantly at the trophozoite and schizont stages of the asexual intraerythrocytic cycle (PMID:33145997). Beyond these interaction, complementation, and expression findings, no further mechanistic detail (e.g. structure or folding kinetics) has been characterized in the available corpus.

1. 2022 Medium

   To ask whether PfPFD6 has identifiable client proteins, its physical association with a candidate parasite substrate was tested, establishing MSP-1 as a binding partner.

   Evidence Pull-down assay with in silico interaction analysis in P. falciparum

   PMID:33145997

   Open questions at the time

   • Single Co-IP/pull-down without reciprocal validation or functional rescue
   • Does not demonstrate that PfPFD6 actually folds or traffics MSP-1
   • Interaction shown for PfPFD6 monomer, not within the assembled complex
2. 2022 Low

   To place PfPFD6 in the parasite life cycle, its stage-specific expression was profiled, showing enrichment at trophozoite and schizont stages.

   Evidence Stage-specific expression analysis in P. falciparum

   PMID:33145997

   Open questions at the time

   • Limited methodological detail reported for the expression assay
   • No quantification of protein versus transcript levels
   • Does not address subcellular localization
3. 2024 Medium

   To establish whether PfPFD6 assembles into a functional co-chaperone, systematic subunit interaction analysis confirmed it participates in the heterohexameric prefoldin complex with PFD1–5.

   Evidence Systematic pairwise biophysical interaction assays across all six subunits in P. falciparum

   PMID:38925325

   Open questions at the time

   • No structural model of the assembled complex
   • Stoichiometry and quaternary architecture not resolved
   • Single lab
4. 2024 Medium

   To connect PfPFD6 to drug resistance, IP-MS in parasites and cross-species complementation tested its relationship to Kelch13 and artemisinin resistance, showing PfPFD6 binds Kelch13 and that its expression confers resistance in yeast PFD6 mutants.

   Evidence Immunoprecipitation coupled MS/MS in P. falciparum 3D7 plus heterologous complementation and ring survival assays in yeast PFD6 mutants

   PMID:38925325

   Open questions at the time

   • Direct genetic manipulation of PfPFD6 in the parasite not shown
   • Mechanistic link between prefoldin folding activity and resistance not resolved
   • Single lab
5. 2024 Medium

   To identify additional clients and a pharmacological handle, IP-MS identified α-tubulin-I as a PfPFD6 partner and showed Biperiden disrupts both PfPFD6–α-tubulin-I and PfPFD6–MSP-1 interactions by blocking complex formation.

   Evidence Immunoprecipitation coupled MS/MS and Biperiden inhibition assay in P. falciparum

   PMID:38925325

   Open questions at the time

   • Whether Biperiden acts directly on PfPFD6 versus another subunit not resolved
   • Folding outcome for α-tubulin-I not measured
   • Single lab

• How PfPFD6 mechanistically contributes within the prefoldin complex to client folding/trafficking and to artemisinin resistance in the parasite itself remains unresolved.
• No direct genetic knockout/knockdown of PfPFD6 in P. falciparum reported
• No structural characterization of PfPFD6 or its client-bound complex
• Causal chain from prefoldin folding activity to Kelch13-mediated resistance not defined